Effectiveness of tranexamic acid in routine performance of total knee replacement surgery

被引:8
作者
Camarasa Godoy, M. A. [1 ]
Serra-Prat, M. [2 ]
Palomera Fanegas, E. [2 ]
机构
[1] Hosp Mataro, Serv Anestesiol Reanimac & Clin Dolor, Barcelona, Spain
[2] Consorci Sanitari Maresme Mataro, Unidad Invest, Barcelona, Spain
来源
REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION | 2008年 / 55卷 / 02期
关键词
Tranexamic acid; Total knee replacement; Hemorrhage; Transfusion; epsilon-aminocaproic acid; Complications;
D O I
10.1016/S0034-9356(08)70513-9
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
OBJETIVOS: To evaluate the effectiveness of treatment with tranexamic acid, compared to absence of antifibrinolytic treatment, in reducing transfusion rates and the number of units of packed red blood cells required in patients undergoing total knee replacement surgery. MATERIAL AND METHODS: We reviewed the medical records of all patients who underwent total knee replacement surgery in a general hospital in 2006. Information was recorded on treatment with tranexamic acid, use of other antifibrinolytic drugs, hemoglobin and hematocrit levels before surgery and 3 days after surgery, patients requiring transfusions, units of packed red blood cells administered, and whether or not drains were clamped within 4 hours. Complications attributable to tranexamic acid (thromboembolic or systemic complications) and preoperative treatment with erythropoietin were also recorded. RESULTS: Data for 166 patients were analyzed. Of these, 120 (723%) received tranexamic acid, 15 (9%) received epsilon-aminocaproic acid, and 31 (18.7%) received no antifihrinolytic treatment. Transfusions were given to 17 patients, of whom 6 (5.0%) had received tranexamic acid, 2 (133%) had received epsilon-aminocaproic acid, and 9 (29.0%) had received no antifibrinolytic treatment. The mean numbers of packed red blood cell units transfused in each group were as follows: 0.075 in the tranexamic acid group, 0.200 in the epsilon-aminocaproic acid group, and 0.645 in the group with no antifibrinolytic treatment (P<001). The mean decrease in hemoglobin levels 5 days after surgery was 3.04 g/dL in the tranexamic acid group, 3.55 g/dL in the B-aminocaproic acid group and 3.76 g/dL in the group with no antifihrinolytic treatment (P<.001). CONCLUSIONS: Tranexamic acid is effective in reducing the percentage of patients requiring transfusions and in the number of units of packed red blood cells required in total knee replacement surgery. No complications attributable to this treatment were found.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 24 条
[1]   Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations - A randomized, blinded clinical trial [J].
BennettGuerrero, E ;
Sorohan, JG ;
Gurevich, ML ;
Kazanjian, PE ;
Levy, RR ;
Barbera, AV ;
White, WD ;
Slaughter, TF ;
Sladen, RN ;
Smith, PK ;
Newman, MF .
ANESTHESIOLOGY, 1997, 87 (06) :1373-1380
[2]   Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty - A prospective, randomised, double-blind study of 86 patients [J].
Benoni, G ;
Fredin, H .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1996, 78B (03) :434-440
[3]   An analysis of blood management in patients having a total hip or knee arthroplasty [J].
Bierbaum, BE ;
Callaghan, JJ ;
Galante, JO ;
Rubash, HE ;
Tooms, RE ;
Welch, RB .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1999, 81A (01) :2-10
[4]  
Bisbe E, 2003, Rev Esp Anestesiol Reanim, V50, P395
[5]   Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement:: a randomized clinical trial [J].
Camarasa, MA ;
Ollé, G ;
Serra-Prat, M ;
Martín, A ;
Sánchez, M ;
Ricós, P ;
Pérez, A ;
Opisso, L .
BRITISH JOURNAL OF ANAESTHESIA, 2006, 96 (05) :576-582
[6]  
Camarasa MA, 2006, MED CLIN-BARCELONA, V127, P572
[7]  
Caravaca F, 2003, NEFROLOGIA CLIN, P725
[8]   Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials [J].
Cid, J ;
Lozano, M .
TRANSFUSION, 2005, 45 (08) :1302-1307
[9]  
Conseiller C, 2000, ENCICL MED QUIR
[10]  
Diaz-Espallardo C, 1999, Rev Esp Anestesiol Reanim, V46, P396